Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.

¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín

Para optimizar los resultados de la búsqueda, se recomienda utilizar términos en inglés.

Método mejorado para diferenciar animales vacunados contra la brucelosis de aquellos infectados por la enfermedad

Resumen

Tipo:
Oferta Tecnológica
Referencia:
TOES20161213001
Publicado:
03/07/2017
Caducidad:
03/07/2018
Resumen:
Una universidad española está desarrollando nuevas herramientas de diagnóstico y vacunas contra la brucelosis. El método desarrollado permite diferenciar animales vacunados contra la brucelosis de aquellos infectados por la enfermedad. Este nuevo método y prueba de diagnóstico basado en DIVA (Differentiation of Infected from Vaccinated Animals) supera las limitaciones de las vacunas actuales contra la brucelosis. La universidad busca empresas o centros de investigación con el fin de establecer acuerdos de licencia o cooperación en materia de investigación para continuar con el desarrollo.

Details

Tittle:
Improved method for differentiating animals vaccinated against brucellosis from those infected with it
Summary:
A Spanish university is developing new brucellosis vaccines and diagnostic tools. This method can be used to differentiate animals that have been vaccinated against brucellosis from those that are infected. This new vaccine tagging method and the appropriate diagnostic test based on the DIVA method (see below) will
overcome the limitations of present brucellosis vaccines. It is looking for companies or research centres interested in license or research cooperation agreements.
Description:
Brucellosis is a disease of worldwide distribution affecting animals and human beings.
Smooth live attenuated vaccines are the most efficient means for prevention and control of animal brucellosis. However, these vaccines carry a wild-type lipopolysaccharide antigen that stimulates an antibody response that is not readily distinguished from that resulting from infection by wild-type brucellae. Since the most effective diagnostic tests detect antibodies to the lipopolysaccharide, vaccination severely compromises the specificity of diagnosis. This is considered the main drawback of current brucellosis vaccines and the main reason limiting their application.

The present invention describes a method for the antigenic tagging of brucellosis smooth vaccines that can be used to differentiate animals that have been vaccinated against brucellosis from those that are infected. This DIVA (Differentiation of Infected from Vaccinated Animals) method is based on the modification of the structure of the O-antigen of the lipopolysaccharide to generate a new immunogenic epitope that is different from those present in wild-type brucellae. This vaccine tagging method can be complemented with an appropriate DIVA test. The method can be applied to Brucella abortus (cattle) and Brucella melitensis (sheep and goats) vaccines.

They are looking for companies or research centres interested in license for the exploitation of this method, or research cooperation for the further development of this method and the production of a field trial.
Advantages and Innovations:
- The development of a new tagging method making possible the differentiation of Brucella infected from Brucella-vaccinated animals will overcome the limitations of present brucellosis vaccines.
- It induces antibodies against the modified Oantigen
and can be easily distinguished from wildtype Brucella strains.
- It can be applied to any classical or new developed smooth Brucella vaccine.
- It will allow sustained brucellosis vaccination, thus resulting in large economic benefits.
Stage of Development:
Available for demonstration
IPs:
Patent(s) applied for but not yet granted,Exclusive Rights
CommeR Statunts Regarding IPR Status:
The patent is still at PCT phase and therefore it is not possible to indicate any country yet; nevertheless there is a firm intention of applying for, at least, the following countries:
- EU countries
- China
- Japan
- India
- USA



Partner sought

Type and Role of Partner Sought:
- Companies working in the heath sector interested in license
- Research centres for the joint development of field tests

Client

Type and Size of Client:
University
Already Engaged in Trans-National Cooperation:
Si
Languages Spoken:
English
Spanish

Keywords

Technology Keywords:
06002006 Biología sintética
06001016 Fisiología
06002004 Ingeniería de proteínas
06001014 Neurología, investigación cerebral
06001006 Vacunas humanas